Related Experiment Video
Updated: Jan 15, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
8.4K
Progress in Disease-Modifying Therapies for Parkinson's Disease
Shuyuan Zhang1,2, Gang Shao3, Bin Wu1,2
1Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China.
Aging and Disease
|October 13, 2025
Summary
Parkinson's disease research focuses on developing disease-modifying therapies (DMTs) by targeting key proteins like alpha-synuclein and organelles. Stem cell strategies also offer new hope for treating this neurodegenerative disorder.
Area of Science:
- Neurodegenerative Disorders
- Parkinson's Disease Pathogenesis
- Therapeutic Development
Background:
- Parkinson's disease (PD) is a prevalent neurodegenerative disorder characterized by progressive dopaminergic neuron loss.
- Current treatments do not halt disease progression, emphasizing the urgent need for disease-modifying therapies (DMTs).
Purpose of the Study:
- To review potential therapeutic targets for PD, including alpha-synuclein, LRRK2, GBA1, the PINK1-Parkin axis, and GLP-1R.
- To summarize organelle dysfunctions (mitochondria, lysosomes, endoplasmic reticulum) in PD.
- To discuss advancements in drug development and stem cell-based therapies for PD.
Main Methods:
- Literature review of potential therapeutic targets and mechanisms in Parkinson's disease.
- Analysis of functional alterations in cellular organelles relevant to PD.
- Summary of current drug development pipelines and stem cell research.
Main Results:
- Several molecular targets (α-synuclein, LRRK2, GBA1, PINK1-Parkin, GLP-1R) show promise for PD treatment.
- Mitochondria, lysosomes, and endoplasmic reticulum dysfunction are key pathological features in PD.
- Progress is being made in developing targeted drugs and stem cell therapies.
Conclusions:
- Understanding PD mechanisms and advancing novel technologies are crucial for developing effective DMTs.
- Targeting specific pathways and organelles, alongside stem cell therapies, represents a promising future for PD treatment.
Related Concept Videos
01:24Parkinson's Disease: Treatment
983
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
983
01:15Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
01:22Alzheimer's Disease: Treatment
822
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
822
01:28Drug Therapy
242
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
242
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:26Psychosis: Goals of Pharmacotherapy
469
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
469